Tyra Biosciences (TYRA) Gains from Investment Securities (2020 - 2026)
Tyra Biosciences (TYRA) reported Gains from Investment Securities of $2375.0 for Q1 2026, down 99.45% on a YoY basis from $434700.0 in Q1 2025, and down 99.98% quarter-over-quarter from $13.6 million in Q4 2025.
Tyra Biosciences (TYRA) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Tyra Biosciences has reported Gains from Investment Securities for 7 years, with the latest figure at $2375.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 99.45% year-over-year to $2375.0; the trailing twelve-month figure through Mar 2026 stood at $2375.0 (down 99.45% YoY), and the FY2025 full-year result was $13.6 million, up 30.16% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $2375.0, down from $13.6 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $13.6 million in Q4 2025, with the low at -$729000.0 in Q4 2022.
- Historically, Gains from Investment Securities has averaged $2.5 million across 5 years, with a median of $200000.0 in 2023.
- The largest YoY upside for Gains from Investment Securities was 8247.5% in 2024 against a maximum downside of 104.99% in 2024.
- Tyra Biosciences' Gains from Investment Securities stood at -$729000.0 in 2022, then surged by 649.38% to $4.0 million in 2023, then plunged by 104.99% to -$200000.0 in 2024, then jumped by 6908.72% to $13.6 million in 2025, then slumped by 99.98% to $2375.0 in 2026.
- The last three Gains from Investment Securities figures came in at $2375.0 (Q1 2026), $13.6 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Tyra Biosciences | 1.67 Bn | 1.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,375.00 |
| Mar 31, 2026 | 2,375.00 |
| Dec 31, 2025 | 13.62 Mn |
| Dec 31, 2025 | 13.62 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Sep 30, 2025 | 4.17 Mn |
| Jun 30, 2025 | 630,585.00 |
| Jun 30, 2025 | 630,585.00 |
| Mar 31, 2025 | 434,700.00 |
| Mar 31, 2025 | 434,700.00 |
| Dec 31, 2024 | -200,000.00 |
| Dec 31, 2024 | -200,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Sep 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 8.35 Mn |
| Mar 31, 2024 | 8.35 Mn |
| Dec 31, 2023 | 4.01 Mn |
| Dec 31, 2023 | 4.01 Mn |